{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T15:50:20Z","timestamp":1791561020222,"version":"4.3.4"},"reference-count":31,"publisher":"Public Library of Science (PLoS)","issue":"9","license":[{"start":{"date-parts":[[2020,9,17]],"date-time":"2020-09-17T00:00:00Z","timestamp":1600300800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000061","name":"Fogarty International Center","doi-asserted-by":"publisher","award":["D43 TW010313"],"award-info":[{"award-number":["D43 TW010313"]}],"id":[{"id":"10.13039\/100000061","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0239344","type":"journal-article","created":{"date-parts":[[2020,9,17]],"date-time":"2020-09-17T18:09:42Z","timestamp":1600366182000},"page":"e0239344","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":7,"title":["Survival of HIV-infected patients with high-grade non-Hodgkin\u2019s lymphomas: A retrospective study of experiences in Zimbabwe"],"prefix":"10.1371","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3772-1018","authenticated-orcid":true,"given":"Maudy C. P.","family":"Manyau","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tinashe","family":"Mudzviti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simbarashe","family":"Rusakaniko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elson T.","family":"Mberi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles C.","family":"Maponga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gene D.","family":"Morse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2020,9,17]]},"reference":[{"key":"pone.0239344.ref001","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1016\/j.jclinepi.2012.03.013","article-title":"GRADE guidelines: 14. Going from evidence to recommendations: the significance and presentation of recommendations","volume":"66","author":"J Andrews","year":"2013","journal-title":"Journal of Clinical Epidemiology"},{"key":"pone.0239344.ref002","doi-asserted-by":"crossref","first-page":"1538","DOI":"10.1182\/blood-2005-04-1437","article-title":"Rituximab does not improve clinical outcome in a randomized phase 3 trial of CHOP with or without rituximab in patients with HIV-associated non-Hodgkin lymphoma: AIDS-Malignancies Consortium Trial 010","volume":"106","author":"LD Kaplan","year":"2005","journal-title":"Blood"},{"key":"pone.0239344.ref003","doi-asserted-by":"crossref","first-page":"3008","DOI":"10.1182\/blood-2009-08-231613","article-title":"Rituximab plus concurrent infusional EPOCH chemotherapy is highly effective in HIV-associated B-cell non-Hodgkin lymphoma","volume":"115","author":"JA Sparano","year":"2010","journal-title":"Blood"},{"key":"pone.0239344.ref004","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1002\/ajh.22275","article-title":"Rituximab in combination with chemotherapy versus chemotherapy alone in HIV-associated non-Hodgkin lymphoma: A pooled analysis of 15 prospective studies","volume":"87","author":"JJ Castillo","year":"2012","journal-title":"Am J Hematol"},{"key":"pone.0239344.ref005","doi-asserted-by":"crossref","first-page":"3251","DOI":"10.1182\/blood-2013-04-498964","article-title":"Treatment factors affecting outcomes in HIV-associated non-Hodgkin lymphomas: a pooled analysis of 1546 patients","volume":"122","author":"SK Barta","year":"2013","journal-title":"Blood"},{"key":"pone.0239344.ref006","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1200\/JGO.17.00084","article-title":"Impact of HIV Infection on the Clinical Presentation and Survival of Non-Hodgkin Lymphoma: A Prospective Observational Study From Botswana.","author":"MG Milligan","year":"2018","journal-title":"JGO"},{"key":"pone.0239344.ref007","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1097\/QAI.0b013e31820c011a","article-title":"Predictors of Survival After a Diagnosis of Non-Hodgkin Lymphoma in a Resource-Limited Setting: A Retrospective Study on the Impact of HIV Infection and Its Treatment","volume":"56","author":"MH Bateganya","year":"2011","journal-title":"JAIDS Journal of Acquired Immune Deficiency Syndromes"},{"key":"pone.0239344.ref008","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1097\/QAI.0b013e3182a03e9b","article-title":"Treatment Outcomes in AIDS-Related Diffuse Large B-cell Lymphoma in the Setting Roll Out of Combination Antiretroviral Therapy in South Africa","volume":"64","author":"P de Witt","year":"2013","journal-title":"JAIDS Journal of Acquired Immune Deficiency Syndromes"},{"key":"pone.0239344.ref009","doi-asserted-by":"crossref","first-page":"e0150445","DOI":"10.1371\/journal.pone.0150445","article-title":"CHOP Chemotherapy for Aggressive Non-Hodgkin Lymphoma with and without HIV in the Antiretroviral Therapy Era in Malawi.","volume":"11","author":"S Gopal","year":"2016","journal-title":"PLoS ONE"},{"key":"pone.0239344.ref010","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1186\/s13027-017-0144-7","article-title":"Outcome of HIV-associated lymphoma in a resource-limited setting of Jos, Nigeria.","volume":"12","author":"OA Silas","year":"2017","journal-title":"Infect Agents Cancer"},{"key":"pone.0239344.ref011","doi-asserted-by":"crossref","first-page":"e0186549","DOI":"10.1371\/journal.pone.0186549","article-title":"Survival and predictors of death in people with HIV-associated lymphoma compared to those with a diagnosis of lymphoma in general population.","volume":"12","author":"A Cingolani","year":"2017","journal-title":"PLoS ONE"},{"key":"pone.0239344.ref012","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1111\/j.1524-4733.2005.00037.x","article-title":"Cost-effectiveness analysis of rituximab combined with chop for treatment of diffuse large B-cell lymphoma.","volume":"8","author":"JH Best","year":"2005","journal-title":"Value Health"},{"key":"pone.0239344.ref013","unstructured":"UNAIDS. UNAIDS: Zimbabwe Profile 2019. https:\/\/www.unaids.org\/en\/regionscountries\/countries\/zimbabwe (accessed November 27, 2019)."},{"key":"pone.0239344.ref014","unstructured":"ZNCR M. Zimbabwe National Registry Cancer Regisry: 2016 Annual Report 2016."},{"key":"pone.0239344.ref015","first-page":"394","article-title":"Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.","volume":"68","author":"F Bray","year":"2018","journal-title":"CA: A Cancer Journal for Clinicians"},{"key":"pone.0239344.ref016","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1186\/s13104-016-2101-8","article-title":"Pre-treatment drug resistance among patients initiating antiretroviral therapy (ART) in Zimbabwe: 2008\u20132010.","volume":"9","author":"M Mungati","year":"2016","journal-title":"BMC Res Notes"},{"key":"pone.0239344.ref017","unstructured":"MoHCC. National Cancer Prevention and Control Strategy for Zimbabwe 2018\u20132022 2019."},{"key":"pone.0239344.ref018","unstructured":"World Bank. Zimbabwe. The World Bank Data n.d."},{"key":"pone.0239344.ref019","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1111\/j.1467-842X.2001.tb00294.x","article-title":"How can I deal with missing data in my study?","volume":"25","author":"DA Bennett","year":"2001","journal-title":"Australian and New Zealand Journal of Public Health"},{"key":"pone.0239344.ref020","doi-asserted-by":"crossref","first-page":"4123","DOI":"10.1200\/JCO.2005.05.4684","article-title":"Phase II Trial of CHOP Plus Rituximab in Patients With HIV-Associated Non-Hodgkin\u2019s Lymphoma.","volume":"24","author":"F Bou\u00e9","year":"2006","journal-title":"JCO"},{"key":"pone.0239344.ref021","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1200\/JCO.2012.42.4648","article-title":"Pegylated liposomal doxorubicin, rituximab, cyclophosphamide, vincristine, and prednisone in AIDS-related lymphoma: AIDS Malignancy Consortium Study 047.","volume":"31","author":"AM Levine","year":"2013","journal-title":"J Clin Oncol"},{"key":"pone.0239344.ref022","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1111\/j.1365-2141.2007.06943.x","article-title":"Safety and efficacy of cyclophosphamide, adriamycin, vincristine, prednisone and rituximab in patients with human immunodeficiency virus-associated diffuse large B-cell lymphoma: results of a phase II trial","volume":"140","author":"J-M Ribera","year":"2008","journal-title":"Br J Haematol"},{"key":"pone.0239344.ref023","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1177\/135965350701200609","article-title":"Treatment and prognosis of AIDS-related lymphoma in the era of highly active antiretroviral therapy: findings from the Swiss HIV Cohort Study.","volume":"12","author":"M Simcock","year":"2007","journal-title":"Antivir Ther (Lond)"},{"key":"pone.0239344.ref024","doi-asserted-by":"crossref","first-page":"2029","DOI":"10.1097\/QAD.0b013e32832e531c","article-title":"Prognosis of HIV-associated non-Hodgkin lymphoma in patients starting combination antiretroviral therapy.","volume":"23","author":"Collaboration of Observational HIV Epidemiological Research Europe (COHERE) study group","year":"2009","journal-title":"AIDS"},{"key":"pone.0239344.ref025","doi-asserted-by":"crossref","first-page":"1731","DOI":"10.3324\/haematol.2014.111112","article-title":"A new prognostic score for AIDS-related lymphomas in the rituximab-era","volume":"99","author":"SK Barta","year":"2014","journal-title":"Haematologica"},{"key":"pone.0239344.ref026","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1182\/blood.V106.11.492.492","article-title":"Revised International Prognostic Index (R-IPI) Is a Better Predictor of Outcome Than the Standard IPI for Patients with Diffuse Large B-Cell Lymphoma (DLBCL) Treated with Rituximab and CHOP (R-CHOP).","volume":"106","author":"LH Sehn","year":"2005","journal-title":"Blood"},{"key":"pone.0239344.ref027","doi-asserted-by":"crossref","first-page":"1460","DOI":"10.1182\/blood.V86.4.1460.bloodjournal8641460","article-title":"International Prognostic Index for aggressive non-Hodgkin\u2019s lymphoma is valid for all malignancy grades","volume":"86","author":"J Hermans","year":"1995","journal-title":"Blood"},{"key":"pone.0239344.ref028","doi-asserted-by":"crossref","first-page":"3083","DOI":"10.1002\/cncr.10583","article-title":"International prognostic index-based outcomes for diffuse large B-cell lymphomas","volume":"94","author":"RB Wilder","year":"2002","journal-title":"Cancer"},{"key":"pone.0239344.ref029","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1002\/cam4.84","article-title":"Cancer survival disparities by health insurance status","volume":"2","author":"X Niu","year":"2013","journal-title":"Cancer Med"},{"key":"pone.0239344.ref030","doi-asserted-by":"crossref","first-page":"1","DOI":"10.21037\/aol.2017.11.01","article-title":"Disparities in lymphoma on the basis of race, gender, HIV status, and sexual orientation.","volume":"1","author":"M Becnel","year":"2017","journal-title":"Ann Lymphoma"},{"key":"pone.0239344.ref031","doi-asserted-by":"crossref","first-page":"290585","DOI":"10.1155\/2013\/290585","article-title":"Clinical Features and Prognosis of CD20 Negative Aggressive B-Cell Non-Hodgkins Lymphoma.","volume":"2013","author":"S Gaur","year":"2013","journal-title":"Lymphoma"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0239344","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,18]],"date-time":"2022-11-18T23:53:47Z","timestamp":1668815627000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0239344"}},"subtitle":[],"editor":[{"given":"Francesco","family":"Bertolini","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2020,9,17]]},"references-count":31,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2020,9,17]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0239344","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,9,17]]}}}